The global biopharma supply chain is entering a new era of uncertainty.

Recent disruptions-from shipping risks in the Red Sea to geopolitical shifts affecting biotech partnerships-are forcing companies to rethink their manufacturing strategies.

Increasingly, pharma leaders are prioritizing resilience over cost optimization, building diversified manufacturing networks across regions.

Increasingly, pharma leaders are asking a different question:
Not “Where is it cheapest?”
but “Where is it safest to manufacture?”

How is your organization preparing its supply chain for the next decade?